Novo Nordisk next-gen shot shows 22% weight loss in early results
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product ...
Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
Novo Nordisk's (NVO) stock was up more than 8% in trading Friday on news the company's latest weight loss product delivered ...
Healio15h
Novel obesity drug induces up to 22% weight loss with no safety concerns
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...
BioSpace17h
Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss
The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...
Healthline1d
Pill Identifier
Need to identify a tablet or capsule? Use our Pill Identifier to find the name and image of an unknown prescription or over-the-counter medication. Start by entering details like pill imprint code ...
The New York Times1d
New York Times - Top Stories
Trump Officials Move to Quickly Expel Migrants Biden Allowed In Temporarily A memo appears to allow Immigration and Customs Enforcement officials to target Biden-era programs that let in more than ...
What's on Netflix1d
Welcome to What's on Netflix
Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...